Eli Lilly has committed up to $1 billion over five years to establish a joint AI innovation laboratory in the San Francisco Bay Area in collaboration with Nvidia. The facility will combine Lilly’s drug-discovery data sets—drawn from decades of clinical trial results—with Nvidia’s latest AI processors to develop proprietary machine-learning models. By co-locating research teams and sharing compute resources, the partnership aims to reduce compound screening times by up to 50%, potentially shortening the pre-clinical phase by months and lowering discovery costs by hundreds of millions of dollars per program.

Lilly’s tirzepatide, marketed for weight loss under the brand name Zepbound, became the world’s top‐selling pharmaceutical product in Q3, generating revenues that propelled the company’s overall sales up 54% year-over-year to $17.6 billion. With global prescriptions exceeding 450,000 in the quarter and penetration above 12% in U.S. bariatric clinics, the therapy is expected to contribute more than $10 billion in annual revenue by 2028 and remain the primary engine driving top-line growth through the end of the decade.

In its latest quarterly report, Lilly delivered adjusted earnings per share of $6.21, a 480% increase compared to the prior-year period, supported by an 83% gross margin and free cash flow exceeding $4 billion. R&D investment rose 22% to $2.8 billion, reflecting continued allocation toward AI platforms and late-stage obesity and diabetes candidates. The company also raised its dividend for the 11th consecutive year, marking a cumulative increase of over 100% during that span, underscoring its commitment to returning capital to shareholders.

Regulators have postponed their decision on Lilly’s investigational oral obesity agent orforglipron, extending the review timeline by three months to April. While the delay pushes back potential U.S. launch by a quarter, it grants additional time for the company to finalize manufacturing scale-up and patient‐support programs. Industry analysts estimate a launch in Q2 could still deliver $1.5 billion in first-year sales if approval is granted, with peak global sales forecasts exceeding $5 billion annually by 2030.